OKYO Pharma Ltd. Files 6-K with SEC
Ticker: OKYO · Form: 6-K · Filed: Apr 4, 2024 · CIK: 1849296
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, disclosure
TL;DR
OKYO Pharma Ltd. filed a 6-K, confirming its UK base and 20-F reporting for investors.
AI Summary
OKYO Pharma Ltd. filed a Form 6-K on April 4, 2024, to report information as a foreign private issuer. The filing indicates the company is based in London, UK, and operates in the biological products sector. It confirms that OKYO Pharma Ltd. files annual reports under Form 20-F.
Why It Matters
This filing provides routine disclosure for OKYO Pharma Ltd. as a foreign private issuer, informing investors about its reporting status and corporate information.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would immediately impact risk.
Key Numbers
- 001-41386 — SEC File Number (Identifies the specific SEC filing for OKYO Pharma Ltd.)
Key Players & Entities
- OKYO Pharma Ltd. (company) — Registrant
- 0001493152-24-013106 (document_id) — Filing Accession Number
- 20240404 (date) — Filing Date
- London (location) — Company Headquarters
- EC2V 6DN (postal_code) — Company Address
- 001-41386 (commission_file_number) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to submit information to the SEC.
Where is OKYO Pharma Ltd. headquartered?
OKYO Pharma Ltd. is headquartered at 9th Floor, 107 Cheapside, London EC2V 6DN.
Does OKYO Pharma Ltd. file annual reports under Form 20-F?
Yes, the filing indicates with a checkmark that the registrant files annual reports under cover of Form 20-F.
What is the SIC code for OKYO Pharma Ltd.?
The Standard Industrial Classification (SIC) code for OKYO Pharma Ltd. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Is OKYO Pharma Ltd. submitting this Form 6-K in paper format?
The filing indicates that the registrant is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).
Filing Stats: 370 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-04-04 06:30:23
Filing Documents
- form6-k.htm (6-K) — 19KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 429KB
- ex99-1_002.jpg (GRAPHIC) — 529KB
- ex99-1_003.jpg (GRAPHIC) — 255KB
- ex99-1_004.jpg (GRAPHIC) — 274KB
- ex99-1_005.jpg (GRAPHIC) — 228KB
- ex99-1_006.jpg (GRAPHIC) — 285KB
- ex99-1_007.jpg (GRAPHIC) — 256KB
- ex99-1_008.jpg (GRAPHIC) — 222KB
- ex99-1_009.jpg (GRAPHIC) — 213KB
- ex99-1_010.jpg (GRAPHIC) — 159KB
- ex99-1_011.jpg (GRAPHIC) — 154KB
- ex99-1_012.jpg (GRAPHIC) — 218KB
- ex99-1_013.jpg (GRAPHIC) — 154KB
- ex99-1_014.jpg (GRAPHIC) — 250KB
- 0001493152-24-013106.txt ( ) — 5024KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-41386 OKYO Pharma Ltd. (Exact Name of Registrant as Specified in Its Charter) 9 th Floor 107 Cheapside London EC2V 6DN (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40 F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K OKYO Pharma Ltd. (the “Company”) intends to conduct meetings with third parties in which its corporate slide presentation will be presented. A copy of the presentation material is attached as Exhibit 99.1 to this report on Form 6-K and is incorporated herein by reference. The information herein and the document attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. EXHIBITS Exhibit Number Description 99.1 Corporate Presentation -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: April 4, 2024 By: /s/ Gary S. Jacob Gary S. Jacob Chief Executive Officer -3-